Stockscreener 앱 받기
7.76
3.05%
0.23
시장 영업 전:
7.84
0.08
+1.03%
전일 마감가:
$7.53
열려 있는:
$7.59
하루 거래량:
4.65M
Relative Volume:
0.61
시가총액:
$1.53B
수익:
-
순이익/손실:
$-29.46M
주가수익비율:
-33.99
EPS:
-0.2283
순현금흐름:
$-28.17M
1주 성능:
+8.53%
1개월 성능:
+9.60%
6개월 성능:
+267.77%
1년 성능:
+397.44%
1일 변동 폭
$7.46
$8.12
1주일 범위
$7.07
$8.125
52주 변동 폭
$1.39
$9.51
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
명칭
Sellas Life Sciences Group Inc
전화
(646) 200-5278
주소
7 TIMES SQUARE, NEW YORK, NY
Compare SLS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
7.76 | 1.52B | 0 | -29.46M | -28.17M | -0.2283 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-07-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-11-01 | 개시 | Oppenheimer | Outperform |
| 2018-04-02 | 개시 | H.C. Wainwright | Buy |
| 2018-03-19 | 업그레이드 | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc 주식(SLS)의 최신 뉴스
SLS Stock Tests $5 Again: Retail Targets ‘No’ Vote On 20M Share Dilution Push Before AML Trial Results - Stocktwits
SLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upside - Stocktwits
SLS Stock Jumps Premarket: CEO Says GPS AML Data Has ‘Very Good Chance’ To Beat Earlier Survival Outcomes - Stocktwits
SLS Stock Falls Premarket: CEO Touts GPS Leukemia Strategy, But Investors Stay Cautious As AML Trial Nears Readout - Stocktwits
SLS Stock Jumps Overnight: ‘Potent’ AML Drug Data Ahead Of Cancer Summit Fuels Fresh Momentum - Stocktwits
SLS Stock Gains Momentum: NVDA, MSFT Investor Loads Up Ahead Of AML Trial Milestone Trigger - Stocktwits
SLS Stock Rises Overnight: Traders Rally Behind Jim Cramer's 'Two Thumbs Up' Call Ahead Of Key AML Readout - Stocktwits
SLS Stock Sparks Retail Buzz Ahead of AACR Presentation On Experimental Cancer Therapy - Stocktwits
SLS CEO Angelos Stergiou Highlights Extended Capital Runway To Pursue Key Milestones, Growth Opportunities – A Look At The Important Numbers - Stocktwits
SLS Stock Pops Big After Hours On Imminent Leukemia Trial Data Readout Optimism - Stocktwits
SLS stock jumps overnight: CEO doubles down on ‘steadfast’ confidence in AML drug and pushes for 20M share plan approval - MSN
SLS stock slides premarket: Traders brace for key arbitration ruling in GPS China payment dispute - MSN
SLS Stock Rallies Ahead Of AML Trial Readout — ‘Pharma Bro’ Martin Shkreli Says He’s Still ‘Very Bearish,’ Predicts Drug Will Fail - Stocktwits
Why did ARM, SLS, EBAY stocks surge to 52-week highs? - MSN
SELLAS Life Sciences Group (SLS) price target increased by 15.38% to 10.20 - MSN
SLS Stock Extends Rally Overnight: CEO Says ‘Bullish’ Leukemia Data Could Drive NCCN Recognition For GPS - Stocktwits
SLS Stock’s Red-Hot Streak Draws Rising Short Bets — Retail Traders Are Now Betting On A Big Pharma Buyout - Stocktwits
SLS Stock Slides Premarket: Traders Brace For Key Arbitration Ruling In GPS China Payment Dispute - Stocktwits
Sellas Life Sciences Draws Significant Retail Buzz As Traders Eye REGAL Phase 3 Catalyst – SLS Stock Soars 15% - Stocktwits
Sellas Life Sciences draws significant retail buzz as traders eye REGAL phase 3 catalyst – SLS stock soars 15% - MSN
SLS stock extends rally overnight: CEO says 'bullish' leukemia data could drive NCCN recognition for GPS - MSN
SLS Stock Takes A Breather After Big Run: Traders Eye AML Summit Featuring Advisor For Clues On Trial Readout - Stocktwits
Sellas Life Sciences Group Inc (SLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):